SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) dropped 2.5% on Friday . The stock traded as low as $10.23 and last traded at $10.39, with a volume of 383,783 shares. The stock had previously closed at $10.66.

The firm has a 50 day moving average of $11.83 and a 200 day moving average of $11.45. The firm has a market capitalization of $519.55 million and a price-to-earnings ratio of 19.28.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share (EPS) for the quarter. The firm had revenue of $39 million for the quarter, compared to analysts’ expectations of $37.90 million. Analysts expect that SciClone Pharmaceuticals Inc. will post $0.33 EPS for the current fiscal year.

An institutional investor recently bought a new position in SciClone Pharmaceuticals stock. Matarin Capital Management LLC purchased a new stake in SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 173,899 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,600,000. Matarin Capital Management LLC owned 0.35% of SciClone Pharmaceuticals as of its most recent SEC filing.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.